Clinical Obesity最新文献

{"title":"Using continuous glucose monitoring (CGM) to understand glucose control in women with obesity during pregnancy","authors":"Sarah A. Price,&nbsp;Alice Lewin,&nbsp;Alison Nankervis,&nbsp;Rahul Barmanray","doi":"10.1111/cob.12717","DOIUrl":"10.1111/cob.12717","url":null,"abstract":"<div>\u0000 \u0000 <p>In women with obesity but without diabetes, the factors driving poor pregnancy outcomes are inadequately understood. This study explores glucose as a potential mediator of adverse pregnancy outcomes in women with obesity. A two-arm observational study was conducted in a single maternity hospital in Melbourne, Australia. Thirty-eight women without diabetes, 20 of normal weight (BMI 20–24.9 kg/m²) and 18 with obesity (BMI ≥30 kg/m²), wore a continuous glucose monitor and had anthropometry and blood samples collected in early, mid and late pregnancy. Subjects who developed gestational diabetes were excluded prior to analysis. Groups were compared with respect to patient-day mean glucose, mean blood glucose, daytime and nighttime glucose AUC, post-prandial glucose AUC, HOMA-IR and QUICKI. Five subjects developed gestational diabetes and were excluded from the analysis. Compared to controls (<i>n</i> = 19), women with obesity (<i>n</i> = 14) had significantly higher PDMG (<i>p</i> &lt; .001), daytime and nighttime glucose AUC (<i>p</i> &lt; .01) and post-breakfast glucose AUC (<i>p</i> &lt; .001 and <i>p</i> = .043) and post-dinner glucose AUC (<i>p</i> &lt; .001) in early and mid-pregnancy. Mean plasma glucose and post-lunch glucose AUC were only higher in women with obesity in early pregnancy (<i>p</i> = .009 and <i>p</i> &lt; .001, respectively). In mid and late pregnancy, HOMA-IR was significantly higher (<i>p</i> &lt; .05) and QUICKI (<i>p</i> &lt; .01) significantly lower in the women with obesity compared to controls. Most parameters that used to assess glycaemic control in pregnancy demonstrated significantly higher plasma glucose in women with obesity compared to controls. This supports the hypothesis that glucose is a mediator of adverse pregnancy outcomes in women with obesity.</p>\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"15 2","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of quality of life and emotional well-being in a bariatric surgery seeking cohort of 1501 multi-ethnic Asian patients","authors":"Wei Yu Chua,&nbsp;Daryl Kai Ann Chia,&nbsp;Yiong Huak Chan,&nbsp;Eugene Kwong Fei Leong,&nbsp;Ashley Chen,&nbsp;Sharen Asif,&nbsp;Yu An Wong,&nbsp;Javis Fung,&nbsp;Rachel Patricia Johnson,&nbsp;Shefali Jay Poojari,&nbsp;Qamaruzaman Syed Gani,&nbsp;Wen Lin,&nbsp;Shu Ning Wai,&nbsp;Geetha Kayambu,&nbsp;Serene Peiying Lim,&nbsp;Wen Joo Neo,&nbsp;Candice Xin Yi Wee,&nbsp;Davide Lomanto,&nbsp;Guowei Kim,&nbsp;Jimmy Bok Yan So,&nbsp;Asim Shabbir","doi":"10.1111/cob.12707","DOIUrl":"10.1111/cob.12707","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The relationship between ethnicity, obesity and health-related quality of life outcomes in a multi-ethnic population remains poorly understood. We aim to investigate the relationship between ethnicity, body mass index (BMI), obesity-associated diseases, as well as determinants of quality of life (QoL) in Southeast Asian patients with obesity. We aim to develop and validate a simple objective score to identify patients with obesity at high risk for major depression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Associations between ethnicity, obesity-associated diseases, BMI and determinants of QoL (Patient Health Questionnaire-9 and 36-Item Short Form Survey) were analysed using multivariate logistic regression in a prospective cohort of 1501 patients with obesity. Multivariate regression and receiver operating characteristics curves were used to develop and validate a novel scoring system to identify patients at risk of major depression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients of Chinese, Malay and Indian ethnicity had increased risk of hypertension (odds ratio [OR]: 1.51 [95% confidence interval [CI]: 1.19–1.92, <i>p</i> &lt; .001]), BMI Class 4 (OR: 17.89 [95% CI: 9.53–33.60, <i>p</i> &lt; .001]) and major depression (OR: 1.71 [95% CI: 1.23–2.39, <i>p</i> = .002]), respectively. Factors associated with major depression (gender, ethnicity, age, obstructive sleep apnoea, Physical Component Score and Mental Component Score scores) were used to create and validate a novel scoring system with an area under curve of 0.812 (95% CI: 0.787–0.837). A cutoff of 4 of 7 points was identified with a sensitivity of 70%, specificity of 81%, positive predictive of 53% and negative predictive value of 90%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The prevalence of metabolic complications from obesity significantly varies with ethnicity. We developed a novel and simple scoring tool combining objective demographic and patient-reported outcomes to screen and triage patients at risk of major depression.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"15 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fructose restriction has beneficial effects on adipose tissue distribution but not on serum adipokine levels: Post-hoc analysis of a double-blind randomized controlled trial","authors":"Michelle A. J. van Oeteren,&nbsp;Nynke Simons,&nbsp;Pomme I. H. G. Simons,&nbsp;Marjo P. H. van de Waarenburg,&nbsp;M. Eline Kooi,&nbsp;Edith J. M. Feskens,&nbsp;E. M. C. (Liesbeth) van der Ploeg,&nbsp;Mathias D. G. Van den Eynde,&nbsp;Alfons J. H. M. Houben,&nbsp;Casper G. Schalkwijk,&nbsp;Martijn C. G. J. Brouwers","doi":"10.1111/cob.12714","DOIUrl":"10.1111/cob.12714","url":null,"abstract":"<p>We aimed to examine the effects of isocaloric fructose restriction on adipose tissue distribution and serum adipokines. Individuals with BMI &gt;28 kg/m² (<i>n</i> = 44) followed a 6-week fructose-restricted diet and were randomly allocated to (double-blind) oral supplementation with fructose (control) or glucose (intervention) powder three times daily. Visceral (VAT) and subcutaneous (SAT) adipose tissue was quantified with MRI. Serum interleukin 6 and 8, tumour necrosis factor alpha and adiponectin levels were measured with sandwich immunoassay. BMI decreased in both groups, but the change did not differ between groups (−0.1 kg/m², 95%CI: −0.3; 0.5). SAT decreased statistically significantly in the control group (−23.2 cm³, 95%CI: −49.4; −4.1), but not in the intervention group. The change in SAT did not differ between groups (29.6 cm³, 95%CI: −1.2; 61.8). No significant differences in VAT were observed within or between study arms. The VAT/SAT ratio decreased statistically significantly in the intervention group (−0.02, 95%CI: −0.04; −0.003) and the change was significantly different between groups (−0.03, 95%CI: −0.54; −0.003). Serum adipokine levels were not affected by the intervention. This study shows that a fructose-restricted diet resulted in a favourable change in adipose tissue distribution, but did not affect serum adipokines. Further studies are warranted to clarify the underlying mechanisms how fructose affects adipose tissue distribution.</p>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"15 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-obesity treatment preferences of healthcare providers and people living with obesity: A survey-based study","authors":"Carel W. Le Roux,&nbsp;Anna Koroleva,&nbsp;Sara Larsen,&nbsp;Ellie Foot","doi":"10.1111/cob.12704","DOIUrl":"10.1111/cob.12704","url":null,"abstract":"<p>A cross-sectional, online survey was conducted in the United Kingdom, France, Germany, and the United States (14 November–22 December 2022) to investigate preferences for anti-obesity medication (AOM) among people with obesity (PwO) and healthcare providers (HCPs). Eligibility: Adult PwO who self-defined their body type as overweight/obese, were trying to lose weight and had BMI ≥30.0 or 27.0–29.9 kg/m² with ≥1 obesity-related complication; HCPs had to see ≥30 PwO in a typical month and be a decision-maker regarding their weight loss. The survey included 2500 PwO and 500 HCPs. Exercise (96%) and diet (90%) were the most common weight management methods; AOM use was low (8%). Key barriers to use of prescribed AOMs among PwO were not wanting to take AOM (34%), side effects concerns (33%), and not trusting AOM (26%). Most HCPs (79%) had prescribed/recommended AOMs. Efficacy was the most common reason for preferring one of the shown product profiles among PwO (60%) and HCPs (86%); improving cardiovascular risk was also important to 95% of HCPs when deciding which AOM to prescribe. AOM preference is largely driven by efficacy. Increasing knowledge could help to address barriers to AOM use and improve outcomes for PwO.</p>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"15 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on: Comparison of fluid and body composition measures in women with lipoedema, lymphoedema, and control participants","authors":"Henrique Jose Pereira de Godoy,&nbsp;Jose Maria Pereira de Godoy","doi":"10.1111/cob.12713","DOIUrl":"10.1111/cob.12713","url":null,"abstract":"<div>\u0000 \u0000 <p>Recently, we read with interest the article ‘Comparison of fluid and body composition measures in women with lipoedema, lymphoedema, and control participants’ by Stellmaker R, Thompson B, Mackie H, Koelmeyer L. <i>Clin Obes</i>. 2024:e12658, is very important study, but some considerations are necessary.</p>\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"15 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gamma-glutamyl transferase: A potential biomarker for pancreas steatosis in patients with concurrent obesity, insulin resistance and metabolic dysfunction-associated steatotic liver disease","authors":"Chileka Chiyanika,&nbsp;Elizabeth Shumbayawonda,&nbsp;Michele Pansini,&nbsp;Kin Hung Liu,&nbsp;Terry Cheuk-Fung Yip,&nbsp;Vincent Wai-Sun Wong,&nbsp;Winnie Chiu Wing Chu","doi":"10.1111/cob.12712","DOIUrl":"10.1111/cob.12712","url":null,"abstract":"<p>To evaluate the relationship between serum gamma-glutamyl transferase (GGT) levels and fatty pancreas in subjects with concurrent obesity, insulin resistance and metabolic dysfunction-associated steatotic liver disease (MASLD) without a history of pancreatitis. From March 2019 to September 2021, 31 adult subjects with concurrent obesity and MASLD were recruited as part of the study investigating the biological impact of bariatric surgery and lifestyle modification on obesity. Chemical shift encoded MRI of the abdomen, LiverMultiScan, anthropometric, clinical and blood biochemistry analyses were performed prior to any intervention at baseline. GGT (<i>p</i> &lt;.001) was significantly different between those ‘with fatty pancreas’ and ‘without fatty pancreas’ groups. GGT (<i>p</i> &lt;.001) was significantly different between those ‘with both metabolic syndrome and fatty pancreas’ and those ‘with metabolic syndrome but without fatty pancreas.’ GGT (<i>p</i> &lt;.001) was also significantly different between those ‘with both diabetes and fatty pancreas’ and those ‘with diabetes but without fatty pancreas’. Logistic regression analysis showed that abnormal GGT levels (<i>p</i> = .010) and Hypertension (<i>p</i> = .045) were significant independent predictors of fatty pancreas. GGT was associated with fatty pancreas by an odds ratio 7.333 (95% [CI]: 1.467–36.664), while the AUROC of GGT in determining fatty pancreas was 0.849. Elevation in serum GGT might be a potential marker to identify fatty pancreas.</p>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"15 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mid-term outcomes of valve replacement surgery with or without coronary artery bypass grafting in patients with overweight and obesity: A cohort study","authors":"Nadia Rajablou,&nbsp;Hasti Tashak Golroudbari,&nbsp;Seyed Hossein Ahmadi Tafti,&nbsp;Jamshid Bagheri,&nbsp;Arezou Zoroufian,&nbsp;Mohammad Sahebjam,&nbsp;Shahrzad Salehbeigi,&nbsp;Zohreh Lesani,&nbsp;Negar Omidi","doi":"10.1111/cob.12710","DOIUrl":"10.1111/cob.12710","url":null,"abstract":"<div>\u0000 \u0000 <p>Current data evaluating outcomes of valve replacement surgery in patients with overweight/obesity is contradictory. There is a scarce study comparing outcomes of valve surgery considering the type of valve involved in the procedure. We followed outcomes in patients with overweight and obesity after valve replacement surgery with or without coronary artery bypass graft (CABG) and also patients with aortic valve replacement (AVR) and mitral valve replacement (MVR), separately to compare their mid-term prognosis in each group. Consecutive patients who had undergone cardiac valve surgery with or without CABG in Tehran Heart Center were enrolled. We enrolled 3158 patients. Median survival was 125.71 <i>±</i> 82.20 weeks in patients with overweight/obesity. We found a significantly higher LVDd, LVDs and RVDd in patients with CABG (51.85 <i>±</i> 7.31, 36.80 <i>±</i> 8.81 and 30.04 <i>±</i> 3.58, respectively) compared to the valve group (50.10 <i>±</i> 6.35 mm, 35.08 <i>±</i> 7.29 mm and 29.76 <i>±</i> 4.07 mm, respectively). All-cause mortality is significantly higher in patients with AVR (5.7%) than those with MVR (3.3%). Patients with CABG are at higher risk of myocardial infarction (MI) compared to the ones without CABG (0.8% vs. 0.1%). No significant interaction was observed between the type of valve surgery (AVR/MVR) or valve surgery combinations (valve/valve + CABG) (<i>p</i>-values = .81 vs. .97, respectively). Post-operative outcomes in patients with overweight/obesity depend on several factors such as type of valve involved and presence of CABG. Risk management can lower the rate of mortality and morbidity in these patients.</p>\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"15 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex differences in perceived discrimination among patients with obesity","authors":"Marianne O. Olaniran,&nbsp;Eda G. Kapti,&nbsp;M. Sunil Mathew,&nbsp;Jeffrey N. Schellinger,&nbsp;Marlyn A. Allicock,&nbsp;Sarah E. Messiah,&nbsp;Jaime P. Almandoz","doi":"10.1111/cob.12711","DOIUrl":"10.1111/cob.12711","url":null,"abstract":"<div>\u0000 \u0000 <p>The negative impacts of perceived discrimination on health have been documented, but how perceptions of discrimination vary by sex among people with obesity (PWO) is not well understood. This study assessed sex differences in perceived discrimination among PWO. This cross-sectional study analysed self-reported data from racially/ethnically diverse PWO attending an academic obesity program. The primary outcome was perceived discrimination, assessed by the Major Experiences of Discrimination (MED) and Everyday Discrimination Scale (EDS). Sex differences were evaluated by univariate and multivariable regression analysis adjusted for key descriptive variables. The final analytical sample included 60 PWO (62% female, 61% non-Hispanic white (NHW), 12% Hispanic, 39% non-Hispanic black (NHB), mean age 53 years, mean BMI 34 kg/m²). Women experienced everyday discrimination 59% less than men but this was not significant (OR 0.41; 95% CI 0.08–2.16; <i>p</i> = .29). Participant highest BMI was correlated with acute discrimination (total MED score) (<i>r</i> = 0.39; <i>p</i> = .0024) and chronic discrimination (total EDS score) (<i>r</i> = 0.28; <i>p</i> = .03). Most participants reported more chronic discrimination compared to acute discrimination (85% vs. 48%). Mean MED (<i>β</i> −0.18; 95% CI –0.93 to +0.56; <i>p</i> = .62) and EDS scores (<i>β</i> −0.25; 95% CI –3.37 to +2.87; <i>p</i> = .87) were not significantly different between women and men. Perceived discrimination was common and experienced equally between men and women with obesity. Incorporating discrimination experiences into obesity care models may be an important step to improving quality of care and outcomes.</p>\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"15 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of dumping and hypoglycaemia symptoms after bariatric surgery: A questionnaire-based cross-sectional study","authors":"Anders Jans,&nbsp;Eva Rask,&nbsp;Johan Ottosson,&nbsp;Eva Szabo,&nbsp;Erik Stenberg","doi":"10.1111/cob.12709","DOIUrl":"10.1111/cob.12709","url":null,"abstract":"<p>Dumping and post-bariatric hypoglycaemia (PBH) are side effects that occur after bariatric surgery. The aim of this study was to estimate the prevalence of dumping and PBH symptoms before Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) at 6 months, 1 year, 2 years and 5 years after surgery in a Swedish population. A cross-sectional single-centre study was performed at Lindesberg Hospital, Region Örebro County, Sweden, between 2020 and 2023. The Swedish version of the Dumping Severity Scale (DSS-Swe) questionnaire, which includes eight items regarding dumping symptoms and six items regarding hypoglycaemia symptoms, was used. A total of 742 DSS-Swe questionnaires were included. The average age at surgery was 42.0 years (standard deviation [SD] = 11.9), and the average body mass index was 41.8 kg/m² (SD = 5.9). The surgical methods consisted of RYGB (66.3%) and SG (33.7%). The proportion of RYGB patients with highly suspected dumping increased from 4.9% before surgery to 26.3% (adjusted odds ratio [OR] = 7.35, 95% confidence interval [CI] = 3.08–17.52) at the 5-year follow-up. PBH symptoms increased from 1.4% before surgery to 19.3% at the 5-year follow-up (adjusted OR = 17.88, 95% CI = 4.07–78.54). For SG patients, no significant increase in dumping or PBH symptoms was observed. In patients with persistent type 2 diabetes (T2D), there were no cases of highly suspected hypoglycaemia following RYGB or SG. Symptoms of dumping and PBH were common after RYGB, while no clear increase was observed after SG. Persistent T2D seems to be a protective factor against PBH symptoms.</p>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"15 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of obesity status and the risk of long-COVID: Isfahan COVID cohort study","authors":"Noushin Mohammadifard,&nbsp;Mohadeseh Arefian,&nbsp;Jamshid Najafian,&nbsp;Azadeh Shahsanaei,&nbsp;Sahel Javanbakht,&nbsp;Shirin Mahmoudi,&nbsp;Fatemeh Nouri,&nbsp;Maedeh Sayyah,&nbsp;Farzaneh Nilforoushzadeh,&nbsp;Mahshid Ahmadian,&nbsp;Fahimeh Haghighatdoost,&nbsp;Nizal Sarrafzadegan","doi":"10.1111/cob.12708","DOIUrl":"10.1111/cob.12708","url":null,"abstract":"<div>\u0000 \u0000 <p>People with COVID-19 infection continue to have their symptoms or develop new ones after recovery. This is called long-COVID syndrome. We aimed to examine the association of general and abdominal obesity with long COVID. This study was conducted using Isfahan COVID Cohort (ICC). Totally 4008 including 3213 hospitalized and 795 non-hospitalized patients with positive RT-PCR were included. Body mass index (BMI) and waist circumference (WC) were calculated. BMI &gt;25 kg/m² and WC &gt;88 cm in women and 102 cm in men were considered generally and abdominally obese, respectively. By using an open-ended questionnaire, subjects were asked whether they had any new or persistent symptom. Reported symptoms were categorized in three different fields including general, cardiac, and respiratory symptoms. Higher BMI and WC tended to increase general symptoms (odds ratio [OR] for BMI = 1.16, 95 % confidence interval (95% CI): 0.97, 1.38, and OR for WC = 1.14, 95% CI: 0.99, 1.32). Higher BMI significantly increased cardiovascular (OR = 1.38, 95% CI: 1.14, 1.67) and respiratory symptoms (OR = 1.43, 95% CI: 1.15, 1.78). Compared with patients with normal WC, the risk of cardiovascular (OR = 1.44, 95% CI: 1.24, 1.69) and respiratory symptoms was significantly higher in subjects with abdominal obesity (OR = 1.31, 95% CI: 1.10, 1.56). We found that general and abdominal obesity were associated with increased risk of cardiovascular and respiratory symptoms in patients with long-COVID symptoms. However, only general obesity was associated with increased risk of general symptoms.</p>\u0000 </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"15 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}